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R&en& after successftd percutattaw transluminal ceronary 
angioplasty is the mnjar clinical problem liniting the hmg~tet’ttt 
etttceey of (hip treattttettt far comnary atbemsclercsis. Recent 
advattcer in the tmdmtmdiwz of the bi&m of ra(emxk indkate 
that in(id hyperplasia ef s&c& muscle &Is is the pwkmdnvlt 
caw for rcs(ottesis. Therefore. therawutir wnts that inhibit 
vascular wee&h muscb cell pmliieration &Id be randidnfe 
drugs to prevent restenesis. 
“aparin has dec,m,ea,e,, aetipmtifer~tivc ellects e” sttmeth 
that leek antkeagtttettt proprtia makes “tee, kleel a@s. 
GlUCKertiitds have rkk &ct5 en bI_tory aed wmnd 
kating events aed inhibit saootb muscle celt gmwth in c&are 
and in animal medels of art&al injury. Recent lalmratery data 
ruggeE, that cembittatien tltenpy with bath low meksdar lveigbt 
kpwin and hydmmikme may be P powcrftd treattttat i-e&ten 
to lb,, rertcImsis. 
Restenosis after successful pwcutsneous transluminal coro- 
nary angioplaaty is the major clinical problem limiting the 
long-term efficacy of this treatment for coronary atheroscle- 
rosis. Much progress has been made recently in our uttder- 
standing of the biologic processes that lead to restenoia. 
Most notably, autopsy specimens from patients with recent 
percutaneous transhtminal coronary angioplasty 11.2) and 
atherectomy samples from patients with restenosis (3 have 
demonstrated that smooth muscle cell intimal hyperplasia is 
the predominant cause for most cases of clinically significant 
restenosis. This review first focuses on the basic mecha- 
nisms involved in smooth muscle cell proliferation and then 
discusses the potential for specific pharmacologic therapy 
with heparin and glucocorticoids. 
Basic Concepts in the Biology of Restenosis 
The normal blwd vessel is a complex organ composed of 
several cell types. including endothelial cells. smooth muscle 
cells. fibmblasts. neurons and macrophages. In the healthy 
adult vessel. the smooth muscle cells exist in a gmwth- 
arrested state lpmliferative rate <O. IWiday 141). It is appar- 
ent that in the atherosclerotic vessel (the usual site for 
coronary angioplasty), dramatic changes in vessel architec 
ture and function have already occurred. Specifically. there 
is strong evidence for impaired ettdothelial cell function (5). 
abered smooth muscle cell vasoreactivity (6). abnormal 
production of platelet-derived growth factor-like milogens 
(7). increased inflammatory cell numbers (8) and increased 
cholesterol and matrix tissue deposition (I). These changes 
indicate that the forces that aommlly limit smooth muscle 
cell mi8ration and proliferetion have already been weak- 
ened. 
Balloon inflation imparts a severe injury to this vessel 
whose defenses have already been severely compromised. 
The vessel response to injury may be analyzed in a temporal 
order, consist& of “trigger” events, smwth muscle cell 
migration. “pbenotypic modularion.” proliferation rmd ii- 
nally quiescellfe (9). 
1. Restenmis trig8er events. The earliest events include 
the effect of mechanical stretch. whih has ken shown (IO) 
to stimulate several signals associated with smooth muscle 
cell proliferation and to influence restenosis rate?.. Within IO 
min of vessel injury. platelets adhere to the damaged suben- 
dothelial matrix and extend pseudopods into the connective 
tissue layer t II). The plafelefs may directly transfer a variety 
of chcmoracric and migrrdory stimuli to both smooth muscle 
and inflammatory cells. These stimuli include plateiet- 
dtrived growth factor, epidemtal growth facts. iemtonin 
and thromboxane. Another trigger of restenosis appears to 
he inflammatory cells, both circulating and resident in the 
atherosclerotic &que. These cells have been shown (12-14) 
to secrete growth and chemotactic factors of smooth muscle 
cells. including macrophage-derived growth factor, interleu- 
kin-l, cycle-oxygenase and lipoxygenase products. Finally. 
we recently showed (15) that oxygen-derived free radicals 
produced after injury may also initiate cell cycle progression 
in cultured smooth muscle ccII3. 
2. Migration. Many of the same factors that act as 
trigger5 and mitogens for smooth muscle cells are also 
chemotactic for these cells t 16). A major factor in the loss of 
~tructuml con~tramts on smooth muscle cells. which allows 
migration, toward the vessel lumen. is the release of prote- 
eses by inflammatory cells and perhaps smooth muscle cells 
1171. resulting in destruction of boundaries such as the 
internal elastic lamina. Substances shown to be chemotactic 
for Smooth muscle cells in vitro include platelet-derived 
growlh factor. serotonin and leukotrienes (16). Recent data 
from Fingerle et al. C 18) indicate that platelet-derived prod- 
ucts play the most important role in the migratory phase of 
vessel injury. 
3. ‘LPhenotypic modulation.” The normal smooth muscle 
cell exists in a growth-arrested slate characterized by low 
level expression of growth-related proteins such as platelet- 
derived growth faclor and growlh factor receptors. Data 
obtained from culture of smooth muscle cells (19) indicate 
thai amooth muscle cells from nonatherosclemtic vessels 
must undergo s’wationa in gene expression before they are 
able to proliferate in response to mitogens. These alterations 
occur in association with acquicition of a “synthetic” phe- 
notype charactcrizcd by loss of contractile protein elements 
(191. It seems probable that smooth muscle cells in athero- 
sclerotic lesions have already undergone this change. as 
demonstrated by the finding of Libby et al. 17). who showed 
the.1 atherosclerotic plaque contains increased amounts of 
platelet-dewed growth factor-like material. 
4. Proliferation. About 505 ,f the medial smooth muscle 
cells activated by injury migrate. These cells then undergo 
swcral cycles of rapid proliferation in the intima, such that 
the total number of smooth muscle cells in the intima 
appears to peak at 2 weeks (20.21). Thus. the proliferative 
phase of restenosi> is co+eted within 2 weeks of injury. 
Subsequent decrcar:s in lumen size appear io be related to 
mechanical factors such BS “elastic recoil” and subsequent 
increases in cell volume and a.ccumulalion of extracellular 
matrix and connective tissue (22). Recent studies 1181 in 
thrombocytopenic animals have indicated lhat the prolifera- 
tive phase is not primarily due to platelet-derived products. 
Rather, autocrine growth mechanisms such as smooth mus- 
cle cell expwsion of platelet-derived growth factor appear 
to be important (7.9.23). 
5. Quiescence. The preceding processes occur in all 
vessels that undergo coronary angioplasty. In the majority 
of patients, however. intimal smooth muscle cell prolifera. 
tion ceases before significant hemodynamic narrowing de- 
velops. The mechanisms responsible for quiescence are 
basically unknown. Possible mechanisms include endothelial 
cell regrowth (241, reestablishment of normal blood Row 
hemodynamics 19.25) and limitation of the inflammatorv 
response. 
Pharmacologic Approaches to 
Limiting Restenosis 
The vessel response to injury is a complex series of 
cellular events that resembles wound repair in many aspects. 
As a normal part of wound repair. there is tissue degradation 
and remodeling, cell migratibm ?nd proliferation and tibro- 
blast invasion and matrix dc osition. In efforts to limit 
intimal hyperplasia to prevent restenosis, it is important to 
allow these normal repurative processes to occur. If phar- 
macologic therapy is too broad in its scope, it may result in 
a weakened vessel susceptible to aneurysm formation. Op- 
timal therapy would allow normal healing of the media and 
reestab!ishment of endothelial-smooth muscle interactions, 
while preventing intimal hyperplasia. 
From the previous discussion of basic biologic concePts. 
a reasonable apt .xich would be to target therapy during the 
1st 2 weeks .award prevention of smooth muscle cell trig- 
gering. migralion and phenotypic modulation. Longer-term 
therapy might be dtrected toward inhibiting smoc?h muscle 
cell a&r~e growth mechanisms, limiting ihe inflammatory 
response and augmenting endothelial cell regrowth. By 
analogy with strategies used in tumor therapy, multiple drug 
regimens may achieve greater growth inhibition with fewer 
side effects. The role of combined therapy with heparin and 
glucacorticoids in this setting is discussed next. 
Heparin to Prevent Restenosis 
Bnsic Mechanisms of Action 
Heparin is a glycosoaminoglycan composed of reptating 
glucosemine and glucuronic acid sugar res;~es. Heparin- 
like molecules have been shown to influence a variety of 
growth processes. including angiogenesis (26) and prolifera- 
tion of Schwann cells (27) and epithelial cells (28). Heperin 
and heparin-like molecules produced by endrthelial cells 
also inhibit smooth muscle cell growth in vitro (29). Smooth 
muscle cells themselves synthesize a heparan sulfate that is 
growth inhibitory (30). Thus, heparin appears to mimic the 
naturally occurring heparan su!fates present in the external 
matrix: these findings suggest that hepsran sulfaes may act 
normally as growth inhibitors. 
Inhibition of smooth muscle cell growth by low molecular 
weight heparin. Heparin causes a cancentraIion.dependent 
inhibition of smooth muscle cell growth in culture from 
human, bovine. rabbit and rat sources. Figure I (31) shows 
the inhibition of serum-stimulated ‘H-thymidine incorpora- 
tion into rat aortic smooth rnu~cle cells treated with I, IO and 
100 &ml of heparin. Karnovsky’s laboratory (30-32) has 
published many studies of the structural elements of heparin 
responsible for growth inhibition. Naturally occurring hep 
arin is heterogeneous, with molecular weights of individual 
molecules ranging from 2.WO to 40,OKt daltons (average 
I5SNM). Approximately 50% of heparin fragments have no 
anticoagulant activity and do not bind with antithrombin. 
These fragments are usually of low molecular weight. Clin- 
Ftgwe 1. Effect of heparin tHepI on deoxyribonucletc acid synthp- 
sis. Vascular smooth muscle cells were growth arrested by 48 h of 
incubation in Dulbecco‘s modified E&A medium supptemcn,e, 
with 0.472 calf serum. Fresh medium containing 0.4% cemm or 10% 
senun plus the indicated concentrations of hcparin IHept was then 
added for 14 h in the presence of 'H-thymidine tl prmttt. tncor- 
prstion c&radioactivity was measured as previously described 131 I. 
ically. low molecular weight forms of heparin ternted “hep- 
arinoids” have been developed by depolymeriration or 
enrichment processes to yield antiproliferative heparinr that 
are nonanticoagulant. Growth inhibition is proportional to 
heparin fragment size. with a maximnl potency observed in 
decamers or larger fragments (33). Measurable inhibition is 
present in pantamers. Inhibition of smwth muscle cell 
growth is specific for hepatin; there is no inhibition by other 
glycosoaminoglycans such as dermatan sulfate. hyalumnic 
acid and chondroitin 4 and 6.sulfates 129). Sulfation and 
acetylation of the sugar moieties is very impertanl: a ncga- 
tive charge at O- position (for example. hydrogen sultitet is 
required, a negative or ncufrat charge at N- position is 
required and 0- oversulfation increases antiproliferative 
activity. 
Mfeltanisms for haPwin growth bsbibitiun. Many mecha- 
nisms have been described for heparin growth inhihttion. 
The earliest mechanism proposed that heparin. which is 
negatively charaed, “scavewed” cationic growth factors 
such as ftbroblast growth f&r and platelet-derived growth 
factor. Recent studies (34) have shown that smooth muscle 
cells bind and internalize heparin consistent with rcceptor- 
mediated endocytosis. Of interest. growth-arrested smooth 
muscle cells bound significantly more heparin than did 
exponentially @xvin8 cells and were SO to RN timer more 
sensitive to the growth-inhibitory e5ccts of heparin 09.34). 
Heparin inhibition is much more e5cctive if smooth muscle 
cells are treated before exposure to mitogens (Fig. 2) (351. 
These data suggest that maximal effectiveness of clinical 
heparln therapy requires administration before smwth rnus- 
cle cell prolifemtion. Several recent studies have provided 
more detailed mechamsms for heparin growth inhibition. 
Reilly et al. (36) showed that the number of epidennal 
growth factor receptors was decreased by 5tI% to f&S. 
Rhure I. except thst the length ofmcubeion in 0.4% calf serum was 
72 h. HePsn” 110 p&d, was added during this period for the 
mdicated number of hours. Fresh medium eontainingOA% serum or 
IO% ssmm plu\ heparin 110 ppmll uss then added lor 24 h in the 
presence of ‘H-thymidinc tt @Xxtt. 
Controversy exists regarding the phase of the cell cycle that 
ts inhibited by heparin: Reilly et al. t3i) presented evidence 
for prevention of entry into the S phase without effect on 
early proto-oncogene expression tc-fos and c-myct. whereas 
Pukac et al. 1381 showed inhibition of c-fns and e-mvr 
expression. events characteristic of progrer& from G,to 
G,. Whatever the precise mechanisms are for hepartn 
growth inhibition. it seems probable that they induce a 
penetic Progrsm that makes smooth rnusctc cells unrespon- 
sive to growth stimuli present in the injured vessel. The fact 
that nonanticoagulant heparins retain this growth-inhibitory 
feature makes them excellent pharmacologic tools to prevent 
restenosis. 
The initial clinical use of hepxin was to prevent cnagu- 
lation. The availability of low molecular weidt heoarins 
lacking anticoagulant-properties has ma& the lon&ertn 
therapeutic use of hepatin for restenasis a realistic possibil- 
ity. As shown in Figure 3. these “heparinoids” lack antic* 
agulant properties. but still inhibb smooth muscle cell 
growth in culture. Thus. these tow molecularweight heparin 
molecules appear to offer great potential for long-term ther- 
apy to prevent intimal hyperplasia. 
Heparin in nnimai mud& of reslenasis. These in vitro 
results have been extended to several models of angioplasty 
injury. Heparin has been shown to inhibit smwth muscle 
cell uuimal hyperplasia in the rabbit iliac batlwn injury 
model (39). as well as in the rat Farotid balloon injury (40) 
and rat carotid air dry injury (41) mad&. Both anticoagulant 
and nonanticoagulant heparins have been effective 141). as 
have been both systemic (39.41) and local (40) administfa- 
Figure 3. EtTect of “heparinoida” on DNA synthesis. Smooth 
muscle cells were growth arresled (as in Fig. II in the presence of 
the indicated concentrations ofheparinoids for 48 h. DNA synthesis 
WBF measured by incorpOration of ‘H-thymidine as described in 
Fiwre I. Heparins were obtained from Choay Institute and Rhone- 
Poulenc. Paris. France. 
lion. These trials have been extended for as long as 3 weeks 
and have demonstrated inhibition of the reduction in luminal 
cross-sectional area as great as 60%. Thus, in animal models 
of restenosis that begin with a relatively normal vessel. 
therapy with heparin alone is effective. 
Clinical trials of hewin theraov. One laree clinical trial 
of heparin therapy in human coronary anery restenosis has 
been reported (421. In this study. 416 patients (469 vessel 
sites) with successfui coronary angioplasty without large 
disrection were randomized to receive heparin (2,ooO U 
inlrwcnous bolus injection. followed by BOO to l.ZtIl U/h for 
I8 to 24 b to achieve an activated partial thromboplastin time 
of approximately 1.5 to 2.5 time> normal) or dextrose. All 
patients also received IO,wO to 15,003 Ll of heparin during 
coronary angioplasty and aspirin for 6 months. There was no 
significant difference in ang~ographic restenosis evaluated at 
180 i 81 days afier coronary andodastv (41.2% in the 
heparin group and 36.7% in -the dextron; group). Major 
limitations of this study were the exclusion of patients with 
a large dissection, the short duration of therapy, the lack of 
complete angiographic follow-up study (58.4% in the heparin 
group and 64.5% in dextrose group) and the lack of pretreat- 
ment with heparin. At the present time, in an ongoing trial 
using the low molecn::rrveight hepatin. enonaoarin. theraov 
includes enoxaparin (3(! &Ida; subcutankously) for’ i 
month. Tbi$ longer duration therapeutic trial should provide 
impilnant dXa regarding the clinical efficacy of heparin. 
Corticosteroids to Prevent Restenosis 
Basic Mechanisms of Action 
Glucocorticoids are potent pharmacologic agents that 
have broad effects on a variety of cellular responses. Ste- 
roids are potent regulators ofcell growth and differentiation. 
The adrenal cortex synthesizer two classes of steroids from 
cholesterol: corticosteroids. which contain 21 carbons. and 
adrenal androgens. which contain 19 carbons. The presence 
of a double bond at carbon 4 and 5 and a hydroxyl arnu~ at 
carbon 21 determines glucocorticoid pot&j. ioltgercdter 
et al. 143) originally observed that glucocorticoidr were 
potent inhibitors of smoo:h muscle cell pro!ifera!in: ood 
smooth muscle cell production of collagen and extrace~!u:ar 
matrix. 
Effects on inflammatory response to arterial injury. Using 
the temporal paradigmjust described for the vessel response 
to injury. it is clear that there are several components of the 
restcnosis process that glucocorticoids can inhibit. Among 
the trigger factors, glucocorticoids are known to possess aa 
“antiplatelet effect” by means of their ability to inhibit 
formation of platelet-activating factor (44). Because gluco- 
corticoids possess potent anti-inflammatory and immuno- 
suppressive effects, they impair many aspects of the inflam- 
matory cell response to arterial injury. Important effects are 
likely to include inhibition of leukocyte migration and de- 
granulation. as well as decreased release of inflammatory 
cell growth faciors (platelet-derived and macropbage- 
derived growth factors) and generation of oxygen-derived 
free radicals. Glucocorticoids inhibit smooth muscle cell 
growth in culture (31,43). In preliminary studies we (45) 
showed that they also inhibit smooth muscle cell chemotaxis 
and autocrine production of platelet-derived growth factor 
A-chain. Finally, glucocorticoids are potent inhibitors of 
collagen synthesis by libroblasts (46). Therefore, they may 
limit the nonproliferative aspects of late restenosis due to 
matrix deposition. 
Inhibition of smooth muscle eelI prollteratlon. Recent 
studies fmm our laboratory (31) have focused on the mech- 
anisms by which glucocorticoids inhibit smooth muscle cell 
proliferation. We hypothesized that glucocorticoids might 
activate a genetic program associated with decreased re- 
sponsiveness to growth factors in much the same mamter as 
proposed for heparin. Cultured rat sonic smooth muscle 
cells were used as the model system for these experiments. 
These cells grow in typical hill and valley configurations in 
culture, reaching rather high density. After exposure to 
hydrocortisone (I @Ml for48 h, cell density was sigttiftcantly 
decreased and cells appeared flatter and more eaithelioid 
(31). When the growth;&es of these cells were examined by 
measuring cell numbers. growth of hydrocottisone-treated 
cells in response to 10% calf serum was inhibited by approx- 
imately 80% compared with control cells (Fig. 4). The e5ect 
was specific for glucocorticoids and not observed for other 
steroids, including testosterone, progesterone and estrogen. 
Meehaaisms. We have discovered several possible mech- 
anisms by which glucocorticoids may inhibit smooth muscle 
cell growth. The most general mechanism appears to be an 
inhibition of protein synthesis, which is rek&d to a decrease 
in ribosomal ribonucleic acid (RNA) synthesis. Recently. we 
observed that glucocorticoids appear to inhibit an autocrine 
growth response. This is suggested by the fact that it took 
Fipure 4. Effect of hydmconisane (HCI on smooth muscle erll 
growth. Cells were plated at 2.W cellslwell and zrowth arrwed for 
3 days in 0.4% calf serum. On day 4. fresh medium comaining IO% 
calf serum (elmed trtangtes,, tO% calf serum with hydroconirone 
(1 pMi @en eircks) or 0.4% calf serum lopn triangles, was added. 
Fresh medium was added everv46 h. Cell counts were wrformed on 
triplicate wells. 
to become apparent. It has been demonstrated 147) that 
cultured smooth muscle cells release platelet-derived growth 
fztor-like material into their culture medium in restxwse to 
angiotensin II. Therefore. we studied the effect df hydro- 
curtisone on the release of this platelet-derived growth 
factor-like material into the culture medium (45). In un- 
treated cells. appmximately 0.3 ng!ml of platelet-dewed 
growth factor-like material was released in response to 
angiotensin II compared with only 0. I2 ng/ml in hydrccorti- 
sane-treated cells (45). Thus. glucocorticoid inhibition of 
smooth muscle cell growth may be caused by inactivation of 
an atUocrine growth mechanism. 
Clinical trials. Beaux of the multiple aspects of the 
restenosis process that may be a&ted by glucocon;coids. it 
is not surprising that several clinical trials have been under- 
taken. The first published clinical trial (481 randomized IO? 
patients with rertenosis after nuccessful coronary angio- 
plasty to receive corticosteroids as part oftheir therapy after 
repeat angioplasty. Fifty-two patients received cotiicoste- 
raids on a regimen that consisted ofmethylprednisolone (125 
ox iotramu&darly) on the evening hefok and the morning 
of coronary angioplasty and oral prednisone (60 mglday) for 
7 dws atler corottary nngioplasty. Patients in both steroid 
and nonsteroid groups also received aspirin. dipyridamole 
and a calcium channel blocker for a2 months. Angiographic 
follow-up data were available in only 54 patients at a mean 
interval of 6 months. There was a high rate of angiographi. 
csliy documented restcoosis in this group of patients Which 
had at least one prior episode of restenosis): 59% in the 
steroid group and 56% in the control group. There was a 
nonsigmficant rend to less clinical restenosis in the steroid 
group with more angina-free patients (76% verws 61%) and 
iewer patient< with class 111 or IV angina (Zti% versus 39%). 
There are several reasons why this trial may have failed to 
show a significant clinical benefit of glucocorticolds: very 
few patients were enrolled. the drug ws administered for 
only 7 days and the study patients were at high risk for 
reswnosis because they exhibited restenosis at least once 
before treatment. 
Multi-Hospital Faten AUantii R&enosis T&al. A much 
larger trial of conicosteroids was carried out in 915 patients 
in rhe #u!!l.Hospitai Eastern Atlantic Restenosis Trial (49). 
In this toal. either placebo or a single dose of mr::qtpred- 
msolone (I 9) i~as infuxd intravenously 2 to 24 h before 
planned coronary anpioplasty. Of the 915 patients entered 
250 patients randomized to receive methyl&dnisolone and 
160 nndomized to placebo were restudied with anticwauhv 
6 ‘c 2 months after coronary angioplasty. The r&ofl&io~ 
restenosis were not significantly different (46% in ihe meth- 
ylprednisolooe group and 39% in the placebo group). Cif 
interest. a retrospective analysis showed a trend toward a 
reduced restenosis rate in methylprednisolone-treated pa- 
tients having lesions characterized as low risk for restenosis. 
The fact that the anti-inflammatory effect of such pulse 
dose steroids on mononuclear cell function should persist for 
several weeks (50) swxests that inhibition of the inilamma- 
tory component of resi&osis alone is oat adequate to inhibit 
intimal hyperplasia. Alternatively. the antiproliferative ef- 
fect may not persist as long as the anti-inflammatory effect. 
suggesting that a longer period of treatment may be oeccs- 
sary. Also. pretreatment of smooth inusck cells in culture 
with either glucocorticoids or heperinr increases their ef- 
ficacy markedly. suggesting that administration up to 48 h 
before angioplasty may be beneticial. 
Heparin nnd Glucocorttcotd Combtnatton 
Therapy to Prevent Restenosir 
The use of multidrug therapy is an important concept that 
has been implicit in the treatment ofrestenosis. Thus, almost 
all patients rouriocly receive aspirin, a calJan channel 
blocker and. frequently. dipyridamole. By analogy to che- 
motherapy in cancer, xtions of several dlugs may he 
synergistic and yield increased growth inhibition with de- 
creased side effects. We utilized this strategy to investigate 
the combined activity of heparin and glucoeorticoids. As 
discussed. they appear to inhibit smooth muscle cell growth 
by different mechanisms. For example. heparin prevents 
gmwth factor induction of the c-fos aud c-m:r proto- 
oncogenes IJW. whereas gh:Locorticoids have no effect on 
these early growth signals. 
In calrere. inhihilion of cell gmwrh by heporin and 
hydmcorrirone is oddirive IFig. 5). At concentrations that 
individually result in only 50% inhibition (IO &ml of hep 
win and IO nM of hydrocortisone), the combination results 
Figure 5. Syncrgiatic c&cls of hepann and hydroconirone Wydro) Figure 6. Synerghtr elfece of law molecular weight hcparin (HepI 
on inhibirmn of cell growth. Cell\ wcrc growth arrested and treated and hydrocortironc (HCI on intimal proliferation. Male New 
as in Figure 4. except that heparin 110 ~glrnll or hydroconisone Zealand While rabbits were used for all experiments. The femoral 
(10 n&f,. or both, wu added ,o ,O’Z calf serum. canal war exoored and the femoral arterv cannulated with a 3F r~~~~ 
in 84% inhibition. This same result was also ohlained with 
low molecular weight heparin obtained from either the 
Choay Institute or Rhone-Poulenc (enoxaparin). 
Rabbilrestenasis model. These in vitroobservations have 
been extended to a rabbit restenosis model (511. In this 
model, the auna was injured by three passages with a 3F 
angioplasty balloon. The rabbits were then trc Ited with I 
week of continuous intravenous low molecular weight hep- 
arin (2.5 mgikg per h). hydrocortisone (I mgIkg per day) or 
their combination administered through an osmoiic pump 
implanted in the femoral vein. Two weeks after balloon 
iniurv. the aorta was oetfusion-fixed and harvested. The 
extent of intimal hyp&lasia was measured by analysis of 
the in!imalmedia thickness for 20 sections (Fig. 6). There 
were significant reductions in treated rabbits with intimai 
media ratios in the control (0.64 + 0.18). heparin (0.23 t 
0.021, hydrocartisone 10.23 ? 0.04) and combination drug 
(0.10 + 0.001) groups. Statistical analysis indicated a signif- 
icant difference (p < 0.05) with the combination therapy in 
comparison with either drug alone. 
Fogany balloon. The balloon was passed p&mally into the aorta. 
inRated and pulled back three times. The rabbits were treated with 
an intravenous bolur injection of low molecular weight Choay 
heparin IS.wO tJ) a the tune of injury. They were then treated for 1 
week with continuous intmvenous heparin (2.1 m&s per h) or 
hydracortisone U m&/kg per day) with use of an Alra osmotic pump 
implanted in the femoral vein. For rabbits treated with both agents. 
Conclusions 
Glucocorticoids and heparins inhibit smooth muscle cell 
growth in culture and in several models of arterial injury and 
restenosis. They appear to work by different mechanisms 
and show synergism in these models. Recent data (52) 
suggest that heparin and the angiotensin-converting enzyme 
inhibitor cilazapril exhibit synergistic inhibition of intimal 
byperplaria in the rat carotid balloon injury model. Despite 
these successes in vitro and in animal models. no effective 
therapy has been demonstrated in clinical situations. 
Porrnrial CUIISPS for the clinical failure include the fact 
that the human corowy anery has as its substrate “ma- 
ture” atherosclerotic lesions. which may have differing 
growth properties. The inability to pretreat and the limita- 
an~addition.4 pump was implanted in the jugular vein. Two weeks 
after balloon injury. the aorta was perfusion Axed and harvested. 
The extent of intimal byperplasia was measured by analysis of 
intimalmedia thickness ratios for 20 sections. Results were statisti- 
cally diRerent for heparin and hydroconisone compared with con- 
trol (p < 0.05) and for the combination compared with all treatments 
(p i 0.051 
cant problems. The availability of a nonanticoagulant hep- 
arin-like molecule that could be administered orally would 
be a sienificant advance. Similarlv. develo~mettt of steroid 
as!iproliferative properties without the deleterious effects of 
glucocortiwids on glucose and salt metabolism would make 
long-term therapy with steroids more feasible. 
Treatment strategies based on the evolving knowledge of 
the biology of intimal hyperplasia and reslenosis. using 
combinations of drugs targeted toward critical temporal and 
cellular events. should lead to a reduction in the frequency of 
restenosis after angioplasty. 
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